Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Eşkazan, Ahmet Emre; Soysal, Teoman

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia [Turk J Hematol]

Turk J Hematol. 2013; 30(2): 211-213 | DOI: 10.4274/Tjh.2012.0013

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

Ahmet Emre Eşkazan¹, Teoman Soysal²
¹Diyarbakır Training And Research Hospital, Department Of Hematology, Diyarbakır, Turkey
²İstanbul University Cerrahpaşa Faculty Of Medicine, Department Of Internal Medicine, Division Of Hematology, İstanbul, Turkey

Dasatinib F317L BCR-ABL Mutasyonu Olan Kronik Miyeloid Lösemi Hastalarında Etkili Olabilir

Ahmet Emre Eşkazan¹, Teoman Soysal²
¹Diyarbakır Eğitim Ve Araştırma Hastanesi, Hematoloji Bölümü, Diyarbakır, Türkiye
²İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Hematoloji Bölümü, İstanbul, Türkiye

Corresponding Author: Ahmet Emre Eşkazan, Türkiye
Manuscript Language: English

CITE

Full Text PDF Download citation RIS EndNote BibTex Medlars Procite Reference Manager Send email to author Similar articles PubMed Google Scholar